Compare Page
GHRP-2 vs Ipamorelin
Quick verdict: GHRP-2 vs Ipamorelin is the GH potency-versus-selectivity trade-off within the ghrelin-receptor agonist class. Both GHRP-2 and ipamorelin activate the same GHS-R1a (ghrelin) receptor to stimulate pulsatile growth hormone release, but they sit at different ends of the selectivity spectrum. GHRP-2 produces one of the strongest GH responses of any synthetic secretagogue but with moderate off-target effects — appetite stimulation, transient cortisol elevation, and mild prolactin increases.[1] Ipamorelin produces dose-dependent GH release without affecting cortisol, ACTH, prolactin, or aldosterone — making it the most selective GH secretagogue ever characterised.[2] The practical question: does maximal GH amplitude or hormonal cleanliness matter more for the research context?
Read the full peptide profiles: GHRP-2 and Ipamorelin.
At a Glance: GHRP-2 vs Ipamorelin
How They Work
GHRP-2 and ipamorelin target the same receptor — GHS-R1a on anterior pituitary somatotroph cells — but with different binding profiles that produce different downstream effects. GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂) is a hexapeptide that produces robust GH release through ghrelin-receptor activation, but its broader receptor interaction profile also activates signalling in the hypothalamic arcuate nucleus (appetite centre) and transiently stimulates ACTH/cortisol and prolactin pathways. This dual-level action — pituitary GH release plus hypothalamic GHRH stimulation — contributes to its potent GH amplitude but also explains the off-target effects.[1]
Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH₂) is a pentapeptide engineered for selectivity. Raun et al. (1998) demonstrated that ipamorelin achieves GH release comparable to GHRP-6 at the pituitary level but without activating the ACTH-cortisol axis, prolactin pathway, or aldosterone secretion. This is attributed to a more specific receptor binding profile — strong GHS-R1a affinity without meaningful activation of other receptor subtypes. The selectivity is the compound’s defining characteristic and the primary reason it is described as “the first selective growth hormone secretagogue.”[2]
Both compounds partially overcome somatostatin’s inhibitory tone on GH release — a property unique to the ghrelin-receptor pathway that GHRH analogs like sermorelin and CJC-1295 do not share. This makes both GHRP-2 and ipamorelin mechanistically complementary to GHRH-pathway compounds for dual-pathway GH stimulation. For GHRP-2 compared to other GHRPs, see GHRP-2 vs GHRP-6.
Evidence Comparison
Both GHRP-2 and ipamorelin have well-established pharmacological profiles but limited large-scale human clinical outcome data. GHRP-2 has been studied since the early 1990s with consistent documentation of its GH potency, appetite effects, and hormonal cross-talk patterns across multiple research groups. Its position as one of the strongest GH secretagogues is well-replicated.[1][3]
Ipamorelin’s evidence is anchored to the Raun (1998) selectivity study, which provides the most detailed comparative pharmacological characterisation of GH secretagogue selectivity in the literature. Additional evidence includes Johansen (1999) demonstrating longitudinal bone growth stimulation in rats and Andersen (2001) showing protection against glucocorticoid-induced bone loss.[4][5] The Sigalos & Pastuszak (2018) review confirmed acceptable safety profiles for GH secretagogues as a class.[3]
Neither compound has large-scale clinical outcome data for body composition, recovery, or aging endpoints comparable to what exists for GHRH analogs like sermorelin (Khorram aging studies) or tesamorelin (JAMA RCTs). The evidence for both is primarily pharmacological and mechanistic rather than clinical-outcome driven. No head-to-head RCT has been conducted.
When Each Fits Better
GHRP-2 may be the stronger fit when:
- Maximum GH amplitude is the primary research endpoint — GHRP-2 consistently produces among the strongest GH responses in the secretagogue class[1]
- Appetite stimulation is acceptable or desired — relevant for caloric surplus and muscle growth research contexts
- The transient cortisol and prolactin effects are manageable within the research design
- Cost considerations favour GHRP-2 over ipamorelin
Ipamorelin may be the stronger fit when:
- Hormonal selectivity is a priority — the cleanest GH secretagogue profile available[2]
- Sleep and recovery research requires no cortisol elevation — cortisol disrupts sleep architecture
- Fat loss or body recomposition contexts where appetite stimulation is counterproductive[2]
- Bedtime administration where cortisol or appetite effects would be undesirable
Head-to-Head
No direct head-to-head trial between GHRP-2 and ipamorelin has been published. The comparison is built on cross-study pharmacological data, which consistently shows GHRP-2 at the high-potency/lower-selectivity end and ipamorelin at the moderate-potency/highest-selectivity end of the GHS-R1a agonist spectrum. The selectivity gradient across the full class runs: ipamorelin (most selective) → GHRP-2 (moderate) → GHRP-6 (least selective).[1][2][3]
The half-life difference is also practically relevant. Ipamorelin has a longer half-life (~2 hours) than GHRP-2 (~15-25 minutes), which affects the duration and shape of the GH pulse. Ipamorelin’s longer persistence may produce a somewhat more sustained GH pulse, while GHRP-2’s shorter window produces a sharper peak. Whether peak amplitude or pulse duration matters more for downstream IGF-1 production and tissue-level effects has not been definitively established.
For most research contexts, the decision framework is straightforward: if clean, selective GH stimulation with minimal hormonal disruption is the priority, ipamorelin is the clear choice. If maximal GH output is the priority and the off-target effects are acceptable, GHRP-2 offers greater raw potency. For researchers interested in dual-pathway approaches, both compounds combine well with GHRH analogs like CJC-1295 or sermorelin.
FAQ
Is ipamorelin better than GHRP-2?
“Better” depends on the research context. Ipamorelin is better for selectivity — it stimulates GH without cortisol, prolactin, or appetite effects.[2] GHRP-2 may be better for raw GH amplitude — it produces one of the strongest GH responses in the secretagogue class.[1] There is no universal “better” — the choice depends on whether selectivity or potency is more important.
Does GHRP-2 increase cortisol?
Yes, mildly and transiently. GHRP-2 produces a small cortisol elevation that typically returns to baseline within 60-90 minutes. This effect is more pronounced than ipamorelin (which has no cortisol effect) but less than GHRP-6. The transient nature means it is generally manageable, but it is relevant for sleep research or contexts where cortisol elevation is specifically undesirable.[1][2]
Which is better for sleep and recovery?
Ipamorelin is generally preferred for sleep/recovery research because it does not elevate cortisol (which can disrupt sleep architecture) and does not stimulate appetite (counterproductive at bedtime). Both compounds enhance slow-wave sleep through GH pulse augmentation, but ipamorelin’s clean profile makes it more suitable for evening administration.[2]
Can either be combined with CJC-1295?
Yes. Both GHRP-2 and ipamorelin work through the GHS-R1a (ghrelin) pathway, while CJC-1295 works through the GHRH receptor. These are independent receptor systems, and dual-pathway stimulation is theorised to produce synergistic GH release. Ipamorelin + CJC-1295 is the most commonly discussed combination due to ipamorelin’s cleaner hormonal profile.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
- Raun K, et al. (same study — primary selectivity characterisation). PMID: 9849822.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
- Johansen PB, et al. Ipamorelin induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343.
- Andersen NB, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Calcif Tissue Int. 2001. PMID: 11322495.